US10561524 — Inserter
Method of Use · Assigned to Bayer Oy · Expires 2029-09-16 · 3y remaining
What this patent protects
This patent protects an inserter for intrauterine systems, specifically designed to receive a frame of the system.
USPTO Abstract
The present invention relates to an inserter for an intrauterine system comprising a handle ( 3 ), and an insertion tube ( 6 ) having a first end and a second end, and being arranged in connection with the handle. The inserter is characterized in that the first end of the insertion tube ( 6 ) comprises at least one frame slot for receiving a frame of the intrauterine system. The invention also relates to a kit comprising an inserter according to the present invention and an intrauterine system, wherein the intrauterine system ( 1 ) comprises a therapeutic component ( 1 b ) and a continuous, closed frame ( 1 a ), the therapeutic component ( 1 b ) being connected to the frame ( 1 a ) at least one point, and therapeutic component ( 1 b ) of the intrauterine system ( 1 ) is at least mainly arranged inside the first end of the insertion tube ( 6 ) and the frame ( 1 a ) of the intrauterine system ( 1 ) is at least mainly arranged outside the first end of the insertion tube ( 6 ).
Drugs covered by this patent
- Jadelle (LEVONORGESTREL) · Fdn Consumer
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2948 |
— | Jadelle |
U-2948 |
— | Jadelle |
U-2948 |
— | Jadelle |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.